Login / Signup

Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.

Masami MikiLingaku LeeTerumasa HisanoRie SugimotoMasayuki Furukawa
Published in: Asia-Pacific journal of clinical oncology (2021)
Loss of adipose tissue or skeletal muscle during L1 had a considerable impact on OS2 in APC refractory to GEM/nabPTX.
Keyphrases
  • skeletal muscle
  • adipose tissue
  • insulin resistance
  • high fat diet
  • metabolic syndrome
  • squamous cell carcinoma
  • type diabetes
  • mesenchymal stem cells
  • cell therapy